Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
| Metrics to compare | LDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLDXPeersSector | |
|---|---|---|---|---|
| P/E Ratio | −15.8x | −14.3x | −0.7x | |
| PEG Ratio | −0.37 | −0.15 | 0.00 | |
| Price/Book | 18.4x | 1.3x | 2.6x | |
| Price / LTM Sales | 9.1x | 5.5x | 3.4x | |
| Upside (Analyst Target) | −52.4% | 0.0% | 40.0% | |
| Fair Value Upside | Unlock | 12.2% | 6.9% | Unlock |